HDL: Fact,

HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk

The measurement of high-density lipoprotein cholesterol is highly utilized by clinicians to help predict cardiovascular risk, but this measure is not causally associated with atherosclerotic cardiovascular disease events. The use of Mendelian randomization studies has led to a change in investigative attention from the high-density lipoprotein cholesterol concentration to its physiological functions. High-density lipoprotein plays key roles in important pathways related to the development of atherosclerotic disease including reverse cholesterol transport, oxidation and inflammation, and endoth

SARS-CoV-2 B.1.1.7 variant associated with increased viral load, but not increased disease seve...

A study published in The Lancet Infectious Diseases suggests that the severe acute respiratory syndr...

Beta-Blockers May Alter Cardiovascular Disease Risk in Patients With HIV, Hypertension

Patients with HIV and hypertension who are treated with beta-blockers for initial blood pressure man...


Suggested videos

Search:
Date
Filters:
The ISH 20
6:13

The ISH 2020 global hypertension practice guidelines

Presenter: Alta Schutte
Cardiology : Hypertension
ESH-ISH 2021
Improving
15:34

Improving the management of hypertension: acting on key factors

Presenter: Michel Burnier
Cardiology : Hypertension
ESH-ISH 2021
Elevated h
10:21

Elevated heart rate in hypertensive patients

Presenter: Stefano Masi
Cardiology : Hypertension
ESH-ISH 2021
Care for p
7:47

Care for patients with HER2-positive breast cancer

Presenter: Hope S. Rugo
Oncology : Breast Cancer
St. Gallen BCC 2021
How can ge
5:53

How can genomic tests help in clinical decision making for adjuvant treatment of ER+ breast cancer?

Presenter: Martine Piccart
Oncology : Breast Cancer
St. Gallen BCC 2021
Highlights
13:01

Highlights of the 17th St. Gallen International Breast Cancer Conference - Breast surgery - Where do we go?

Presenter: Michael Gnant
Oncology : Breast Cancer
St. Gallen BCC 2021
Highlights
4:21

Highlights of the 17th St. Gallen International Breast Cancer Conference - Breast surgery - Take home messages

Presenter: Michael Gnant
Oncology : Breast Cancer
St. Gallen BCC 2021
Recognizin
17:43

Recognizing and Addressing Risk in Patients with HR-positive, HER2-negative Early Breast Cancer

Presenter: William J. Gradishar
Oncology : Breast Cancer
St. Gallen BCC 2021
The role o
14:49

The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer

Presenter: Peter Schmid
Oncology : Breast Cancer
St. Gallen BCC 2021
De-escalat...
9:42

De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy

Presenter: Fatima Cardoso
Oncology : Breast Cancer
St. Gallen BCC 2021
Making opt
10:35

Making optimal treatment decisions for patients with HER2-positive eBC

Presenter: Giampaolo Bianchini
Oncology : Breast Cancer
St. Gallen BCC 2021
Global Per
8:14

Global Perspectives on Breast Cancer Care during the COVID-19 Pandemic how BC was managed and lessons Learned

Presenter: Lidia Schapira
Oncology
SABCS 2020
Effect of
4:54

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Presenter: John Kuruvilla
Hematology
ASH 2020
Optimal Du
3:55

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Presenter: Dennis Kim
Hematology
ASH 2020
Novelties
8:45

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

Presenter: Joseph Mikhael
Hematology
ASH 2020
Omitting R
5:14

Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer

Presenter: Ian Kunkler
Oncology
SABCS 2020
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology